| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Joseph Jankovic | Q6284337 |
| Benzi M Kluger | Q64856652 | ||
| P2093 | author name string | Wallace Jones | |
| Piera Triolo | |||
| P2860 | cites work | Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease | Q48435185 |
| The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia | Q48890770 | ||
| The clinical features of psychogenic movement disorders resembling tics. | Q51183278 | ||
| (+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters | Q51620133 | ||
| A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. | Q51853893 | ||
| Effective treatment of Tourette's syndrome with marijuana. | Q53986251 | ||
| Cannabinoid, CB1 agonists in cervical dystonia: Failure in a phase IIa randomized controlled trial | Q57083745 | ||
| Marijuana and Tourette's syndrome | Q68049272 | ||
| Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study | Q72656516 | ||
| Tetrahydrocannabinol potentiates reserpine-induced hypokinesia | Q72916142 | ||
| Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol | Q74611800 | ||
| A dramatic response to inhaled cannabis in a woman with central thalamic pain and dystonia | Q74619834 | ||
| Cannabis-induced propriospinal myoclonus | Q80201669 | ||
| Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys | Q80609691 | ||
| Cannabis sativa and dystonia secondary to Wilson's disease | Q80609849 | ||
| Cannabinoids improve driving ability in a Tourette's patient | Q84336229 | ||
| Synthetic cannabinoid overdose in a 20-year-old male US soldier | Q85911058 | ||
| N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor | Q21093349 | ||
| Cannabinoids for Tourette's Syndrome | Q24240148 | ||
| Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker | Q24601670 | ||
| Human cannabinoid pharmacokinetics | Q24652736 | ||
| Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders | Q26823267 | ||
| Adverse health effects of marijuana use | Q26861513 | ||
| Cannabinoids control spasticity and tremor in a multiple sclerosis model | Q28138564 | ||
| Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets | Q28203208 | ||
| The enigmatic pharmacology of GPR55 | Q28235873 | ||
| Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice | Q28250525 | ||
| Identification and functional characterization of brainstem cannabinoid CB2 receptors | Q28276972 | ||
| International Union of Pharmacology. XXVII. Classification of cannabinoid receptors | Q29616832 | ||
| Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. | Q33845285 | ||
| Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial | Q33958602 | ||
| Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance | Q33964368 | ||
| Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. | Q33965686 | ||
| Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity | Q34002281 | ||
| Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. | Q34025116 | ||
| Open label evaluation of cannabidiol in dystonic movement disorders | Q34050762 | ||
| Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease. | Q34098292 | ||
| Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia | Q34113369 | ||
| Therapeutic aspects of cannabis and cannabinoids | Q34130996 | ||
| Psychogenic tremor: a video guide to its distinguishing features | Q34169551 | ||
| Cannabinoid modulation of the dopaminergic circuitry: implications for limbic and striatal output | Q34248777 | ||
| Endocannabinoid signaling and synaptic function | Q34304094 | ||
| The pharmacologic and clinical effects of medical cannabis. | Q34326515 | ||
| Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms | Q34349067 | ||
| Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease | Q44285779 | ||
| Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism | Q44418544 | ||
| Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate | Q44511287 | ||
| Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function | Q44793025 | ||
| Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease | Q44931450 | ||
| Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. | Q45217300 | ||
| Controlled clinical trial of cannabidiol in Huntington's disease | Q45293556 | ||
| UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. | Q45297533 | ||
| Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo | Q45299326 | ||
| Nabilone increases choreatic movements in Huntington's disease | Q45299472 | ||
| The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease | Q45300428 | ||
| The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. | Q45302088 | ||
| Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. | Q45303268 | ||
| Nabilone could treat chorea and irritability in Huntington's disease | Q45303424 | ||
| Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease | Q45305400 | ||
| Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism | Q45310537 | ||
| The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. | Q46026291 | ||
| Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease | Q46443478 | ||
| High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. | Q46456086 | ||
| A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease | Q46491157 | ||
| The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: implications in Parkinson's disease | Q46552546 | ||
| Therapeutic effects of Delta9-THC and modafinil in a marmoset Parkinson model | Q46789289 | ||
| Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome | Q46859134 | ||
| Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial | Q48065074 | ||
| Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors | Q48087305 | ||
| Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series | Q48105623 | ||
| Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain | Q48139478 | ||
| Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action | Q48309971 | ||
| Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties | Q48324018 | ||
| Colorado tackles medical implications of marijuana | Q48367047 | ||
| Endocannabinoid modulation of dopaminergic motor circuits. | Q38018946 | ||
| Treatment of Tourette syndrome with cannabinoids | Q38063066 | ||
| The pathophysiology of symptomatic propriospinal myoclonus | Q38224389 | ||
| Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease | Q39365419 | ||
| The effect of cannabis on tremor in patients with multiple sclerosis | Q39381983 | ||
| Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease | Q40358139 | ||
| Prevalence and correlates of drug use and dependence in the United States. Results from the National Comorbidity Survey | Q40992443 | ||
| Marijuana for parkinsonian tremor | Q41369366 | ||
| Cannabinoid receptor agonist protects cultured dopaminergic neurons from the death by the proteasomal dysfunction | Q41968489 | ||
| Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism | Q42095959 | ||
| The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats | Q42445636 | ||
| Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease | Q42464432 | ||
| Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen | Q42487505 | ||
| Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. | Q42500348 | ||
| Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 | ||
| Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. | Q42517324 | ||
| Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. | Q42624110 | ||
| Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). | Q42646021 | ||
| Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease | Q42695373 | ||
| Effects of cannabinoid CB1 receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys | Q42844506 | ||
| Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease | Q42851005 | ||
| The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats | Q42871461 | ||
| Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. | Q42988084 | ||
| Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report | Q43045883 | ||
| A pilot study using nabilone for symptomatic treatment in Huntington's disease | Q43257764 | ||
| Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. | Q43266820 | ||
| Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats | Q43425029 | ||
| Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease | Q43504648 | ||
| Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease | Q43669613 | ||
| Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. | Q43683165 | ||
| Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study | Q43820144 | ||
| Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. | Q44102387 | ||
| Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia | Q44209138 | ||
| Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease | Q44237885 | ||
| Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study | Q34358022 | ||
| Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study | Q34409345 | ||
| Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology | Q34417710 | ||
| Probability and predictors of the cannabis gateway effect: a national study | Q34435738 | ||
| Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome | Q34486318 | ||
| Cannabinoid function in learning, memory and plasticity | Q34510858 | ||
| Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial | Q34543217 | ||
| Effect of cannabinoids on spasticity and ataxia in multiple sclerosis | Q34676919 | ||
| Tetrahydrocannabinol for tremor in multiple sclerosis | Q34708416 | ||
| The perceived effects of smoked cannabis on patients with multiple sclerosis | Q34742477 | ||
| Cannabidiol for the treatment of psychosis in Parkinson's disease | Q34830827 | ||
| Cannabis smoking and risk of lung cancer in men: a pooled analysis of three studies in Maghreb | Q34895727 | ||
| Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease | Q35193305 | ||
| The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats | Q35740152 | ||
| Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors. | Q36056302 | ||
| Cannabinoid-based drugs as anti-inflammatory therapeutics | Q36111923 | ||
| Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. | Q36248857 | ||
| Sensory aspects of movement disorders | Q36595746 | ||
| Endocannabinoids in basal ganglia circuits: implications for Parkinson disease | Q36884599 | ||
| Modulating the endocannabinoid system in human health and disease--successes and failures | Q36933683 | ||
| Pharmacokinetic and pharmacodynamic profile of supratherapeutic oral doses of Δ(9) -THC in cannabis users | Q36951509 | ||
| Cannabinoids and neuroprotection in basal ganglia disorders. | Q36977766 | ||
| Steppingstone and gateway ideas: a discussion of origins, research challenges, and promising lines of research for the future | Q36989649 | ||
| The seek of neuroprotection: introducing cannabinoids. | Q37067463 | ||
| Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. | Q37253331 | ||
| WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. | Q37371387 | ||
| Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression | Q37414566 | ||
| Designing clinical trials for dystonia | Q37506514 | ||
| The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation | Q37532968 | ||
| Anandamide and the vanilloid receptor (TRPV1). | Q37568663 | ||
| Cannabinoids and neurodegenerative diseases | Q37617447 | ||
| Prevalence and correlates of alcohol and cannabis use disorders in the United States: results from the national longitudinal study of adolescent health | Q37658318 | ||
| The Multiplicity of Action of Cannabinoids: Implications for Treating Neurodegeneration | Q37793366 | ||
| Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine | Q37871980 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cannabinoids | Q422936 |
| P304 | page(s) | 313-327 | |
| P577 | publication date | 2015-02-04 | |
| P1433 | published in | Movement Disorders | Q1486418 |
| P1476 | title | The therapeutic potential of cannabinoids for movement disorders | |
| P478 | volume | 30 |
| Q42087548 | A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease |
| Q47101767 | A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders |
| Q38392800 | A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease. |
| Q36157657 | Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe? |
| Q40701861 | Cannabinoids for the Treatment of Movement Disorders. |
| Q42258332 | Cannabinoids in Parkinson's Disease |
| Q27336419 | Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics |
| Q92583461 | Complementary Therapies for Parkinson's Disease: What's Promoted, Rationale, Potential Risks and Benefits |
| Q41761143 | Does modulation of the endocannabinoid system have potential therapeutic utility in cerebellar ataxia? |
| Q38811387 | Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia |
| Q50043450 | Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease |
| Q64299310 | Marijuana for Parkinson's Disease? |
| Q40458313 | Media hype: Patient and scientific perspectives on misleading medical news. |
| Q59477201 | Medical treatment of dystonia |
| Q92298782 | Nabilone for non-motor symptoms of Parkinson's disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study) |
| Q26766090 | Recent Advances in Understanding and Managing Tourette Syndrome |
| Q30373216 | Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson's disease patients in colorado. |
| Q42495608 | The bright side of psychoactive substances: cannabinoid-based drugs in motor diseases. |
| Q38423817 | The role of cannabinoids and leptin in neurological diseases |
| Q34491345 | Therapeutic Developments for Tics and Myoclonus |
| Q47977953 | Treatment options for chorea |
Search more.